| COVID-19 Clinical Research Studies | Lifetime | 42 | SA 3 | 99.69 |
| SARS-CoV-2 and COVID-19 Research | Lifetime | 59 | SA 2 | 99.67 |
| Long-Term Effects of COVID-19 | Lifetime | 46 | SA 2 | 99.26 |
| COVID-19 and Mental Health | Lifetime | 43 | SA 1 | 99.34 |
| COVID-19 epidemiological studies | Lifetime | 41 | SA 2 | 99.48 |
| COVID-19 Impact on Reproduction | Lifetime | 23 | SA 1 | 98.89 |
| Travel-related health issues | Lifetime | 10 | SA 2 | 99.15 |
| SARS-CoV-2 detection and testing | Lifetime | 46 | SA 2 | 98.69 |
| Vaccine Coverage and Hesitancy | Lifetime | 81 | SA 2 | 99.08 |
| COVID-19 diagnosis using AI | Lifetime | 49 | SA 5 | 98.51 |
| Antibiotic Use and Resistance | Lifetime | 100 | SA 1 | 99.25 |
| COVID-19 Pandemic Impacts | Lifetime | 76 | SA 3 | 97.91 |
| Antibiotic Resistance in Bacteria | Lifetime | 637 | SA 1 | 98.23 |
| Nosocomial Infections in ICU | Lifetime | 194 | SA 4 | 98.10 |
| COVID-19 and healthcare impacts | Lifetime | 534 | SA 4 | 94.33 |
| Bacterial Identification and Susceptibility Testing | Lifetime | 454 | SA 1 | 97.64 |
| Bacillus and Francisella bacterial research | Lifetime | 253 | SA 2 | 95.86 |
| Influenza Virus Research Studies | Lifetime | 763 | SA 2 | 96.89 |
| Diagnosis and treatment of tuberculosis | Lifetime | 360 | SA 2 | 95.67 |
| Pneumonia and Respiratory Infections | Lifetime | 988 | SA 3 | 97.02 |
| Streptococcal Infections and Treatments | Lifetime | 735 | SA 2 | 96.42 |
| Antimicrobial Resistance in Staphylococcus | Lifetime | 865 | SA 1 | 96.54 |
| Antifungal resistance and susceptibility | Lifetime | 999 | SA 3 | 95.58 |
| Fungal Infections and Studies | Lifetime | 763 | SA 2 | 95.67 |
| Brucella: diagnosis, epidemiology, treatment | Lifetime | 211 | SA 2 | 94.37 |
| Infectious Diseases and Tuberculosis | Lifetime | 911 | SA 3 | 93.81 |
| Urinary Tract Infections Management | Lifetime | 859 | SA 1 | 95.35 |
| Infection Control and Ventilation | Lifetime | 345 | SA 2 | 93.87 |
| Poxvirus research and outbreaks | Lifetime | 390 | SA 1 | 93.21 |
| Infection Control in Healthcare | Lifetime | 374 | SA 4 | 90.93 |
| Syphilis Diagnosis and Treatment | Lifetime | 812 | SA 3 | 89.21 |
| Actinomycetales infections and treatment | Lifetime | 632 | SA 2 | 76.71 |
| Infections and bacterial resistance | Lifetime | 968 | SA 4 | 74.30 |
| COVID-19 Clinical Research Studies | 2021-2025 | 72 | SA 2 | 99.52 |
| SARS-CoV-2 and COVID-19 Research | 2021-2025 | 110 | SA 2 | 99.45 |
| Bacillus and Francisella bacterial research | 2021-2025 | 6 | SA 1 | 98.35 |
| Long-Term Effects of COVID-19 | 2021-2025 | 85 | SA 2 | 98.82 |
| Poxvirus research and outbreaks | 2021-2025 | 12 | SA 2 | 98.04 |
| Vaccine Coverage and Hesitancy | 2021-2025 | 82 | SA 2 | 98.36 |
| Herpesvirus Infections and Treatments | 2021-2025 | 34 | SA 2 | 97.33 |
| COVID-19 and Mental Health | 2021-2025 | 342 | SA 5 | 96.71 |
| Travel-related health issues | 2021-2025 | 11 | SA 4 | 96.45 |
| Antibiotic Use and Resistance | 2021-2025 | 221 | SA 2 | 95.14 |
| COVID-19 epidemiological studies | 2021-2025 | 524 | SA 15 | 93.79 |
| Antibiotic Resistance in Bacteria | 2021-2025 | 802 | SA 13 | 92.28 |
| COVID-19 Impact on Reproduction | 2021-2025 | 395 | SA 1 | 89.32 |
| SARS-CoV-2 detection and testing | 2021-2025 | 902 | SA 8 | 87.55 |
| Nosocomial Infections in ICU | 2021-2025 | 629 | SA 8 | 74.04 |
| Heparin-Induced Thrombocytopenia and Thrombosis | 2021-2025 | 589 | SA 1 | 64.62 |
